Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Top Cited Papers
- 21 September 2010
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 11 (10) , 962-972
- https://doi.org/10.1016/s1470-2045(10)70203-5
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson ExperienceJournal of Clinical Endocrinology & Metabolism, 2010
- Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center ExperienceJournal of Clinical Endocrinology & Metabolism, 2009
- Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005Cancer, 2009
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation TrialJournal of Clinical Oncology, 2009
- Phase II Trial of Sorafenib in Metastatic Thyroid CancerJournal of Clinical Oncology, 2009
- Rising Thyroid Cancer Incidence in the United States by Demographic and Tumor Characteristics, 1980-2005Cancer Epidemiology, Biomarkers & Prevention, 2009
- Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2009
- Phase II Trial of Sorafenib in Advanced Thyroid CancerJournal of Clinical Oncology, 2008
- New therapeutic approaches for metastatic thyroid carcinomaThe Lancet Oncology, 2007
- Increased Expression of Vascular Endothelial Growth Factor C in Papillary Thyroid Carcinoma Correlates with Cervical Lymph Node MetastasesClinical Cancer Research, 2005